Core Viewpoint - The article explores the rich history and cultural significance of traditional Chinese medicine brand Tong Ren Tang, emphasizing its commitment to quality and community service over centuries [1][4][7]. Group 1: Company History and Philosophy - Tong Ren Tang was founded during the Kangxi era of the Qing Dynasty by Le Xianyang, initially named "Tong Ren Tang Pharmacy" [4]. - The brand has a legacy of over 357 years, known for its high-quality herbal medicines and adherence to traditional manufacturing principles [4][5]. - The motto "同修仁德 济世养生" reflects the company's dedication to benevolence and health care for the public [4][7]. Group 2: Product Offerings - The store offers a wide range of essential health products, including remedies for common ailments such as colds and digestive issues, particularly during the winter-spring transition [5][6]. - Classic formulas like Liu Wei Di Huang Wan and its variations are available, showcasing the brand's commitment to traditional Chinese medicine [6]. - The store also features a cultural section with creative products that appeal to tourists, enhancing the shopping experience [6]. Group 3: Community Engagement and Cultural Significance - Tong Ren Tang has a history of community involvement, such as providing lighting for safe passage home in the past, which has ingrained its name in the public consciousness [7]. - The company continues to support cultural initiatives, such as the "Tong Ren Literature Academy," fostering literary talent among youth [7]. - The upcoming live event aims to discuss the history and cultural impact of old brands like Tong Ren Tang, promoting traditional Chinese culture [8][9].

Industry Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Outperform the Market" and is maintained [1] Core Insights - The report highlights the acceleration of policy support for the optimization and transformation of the traditional Chinese medicine (TCM) industry, benefiting leading TCM companies [4][15] - The implementation plan for the high-quality development of the TCM industry (2026-2030) aims to establish a collaborative development system for the entire industry chain by 2030, fostering leading TCM enterprises and promoting the approval of innovative TCM drugs [4][15] - The report identifies specific companies that are expected to benefit from these policies, including Yiling Pharmaceutical, Tianshili, Kangyuan Pharmaceutical, and Fangsheng Pharmaceutical [5][16][17] Summary by Sections Industry Overview - The closing index for the pharmaceutical and biotechnology sector is 8350.08, with a 52-week high of 9323.49 and a low of 6876.88 [1] Recent Market Performance - During the week of February 2 to February 6, 2026, the A-share pharmaceutical and biotechnology sector rose by 0.14%, outperforming the CSI 300 index by 1.47 percentage points and the ChiNext index by 3.43 percentage points [6][18] - The TCM sector ranked first among sub-sectors with a weekly increase of 2.56%, while other biopharmaceutical sectors experienced a decline of 2.42% [18] Investment Recommendations 1. **Innovative Drugs**: The innovative drug sector is expected to continue to be a strong growth area, with a focus on companies with high certainty and relatively low business development (BD) expectation disturbances, such as Innovent Biologics, Sanofi, and others [7][21] 2. **Medical Devices**: The medical device sector is showing signs of recovery, with leading companies improving their performance in Q3. The report suggests that the pressure from centralized procurement is diminishing, which may lead to valuation recovery [8][23] 3. **Traditional Chinese Medicine**: The report is optimistic about TCM companies benefiting from centralized procurement and basic drug policies, with specific companies highlighted for their potential growth [29][30] 4. **AI in Healthcare**: Companies leveraging AI technology in drug development and medical services are expected to see significant benefits, with specific companies listed for each AI application area [9][32][34]

Investment Rating - The report upgrades the investment rating for the pharmaceutical and biotechnology industry to "Recommended" [1][42]. Core Insights - The pharmaceutical sector has shown resilience, with a year-to-date return of 3.28%, outperforming the Shanghai Composite Index by 2.99 percentage points [9][23]. - The report highlights the continuous support from policies, particularly for the traditional Chinese medicine (TCM) sector, which is expected to see significant growth due to government initiatives aimed at enhancing the industry [15][17]. - The report emphasizes the importance of innovation in the pharmaceutical sector, noting that domestic companies are gradually improving their innovation capabilities [42]. Summary by Sections Recent Performance - The Shanghai Composite Index fell by 1.33% while the pharmaceutical sector rose by 0.14%, ranking 15th among 31 primary sub-industries [14][23]. - Within the pharmaceutical sub-sectors, traditional Chinese medicine, medical services, and other segments showed varying performance, with traditional Chinese medicine increasing by 2.56% [14][23]. Policy Developments - On February 5, 2026, the Ministry of Industry and Information Technology and other departments released the "Implementation Plan for High-Quality Development of the Traditional Chinese Medicine Industry (2026-2030)," focusing on enhancing the resilience and stability of the TCM supply chain [15][17]. - The plan aims to improve the quality and stable supply of TCM materials and products, which is crucial for the long-term development of the industry [15][17]. Market Dynamics - The report notes that the TCM sector is expected to experience a recovery in performance starting from mid-2025, with improved financial results anticipated in 2026 [9][17]. - The comprehensive index for TCM materials has been declining since July 2024, which is expected to alleviate cost pressures for TCM companies in 2026 [9][17]. Valuation Metrics - As of February 6, 2026, the pharmaceutical sector's valuation stands at 33.3 times PE, with a premium of 32% compared to the overall A-share market (excluding financials) [24]. - The TTM valuation is at 29.4 times PE, below the historical average of 34.9 times PE, indicating potential for growth [24]. Key Companies to Watch - The report suggests focusing on companies such as Aidi Pharmaceutical, Huadong Medicine, Kangnuo Pharmaceutical-B, and others, which are positioned well within the TCM sector and are expected to benefit from policy support and market dynamics [35][43].

近日，工业和信息化部、国家卫生健康委、国家中医药局等八部门联合印发《中药工业高质量发展实施 方案（2026—2030年）》，提出到2030年，中药工业全产业链协同发展体系初步形成。 她表示，以植物药材种植为例，高标准基地建设不仅要重视产地和种源，更要尊重中药材生长规律，因 地制宜发展生态种植，从源头提升中药材质量的稳定性和一致性。 对于珍稀中药材，截至2025年6月，我国已支持红景天、川贝母等14种濒危中药材人工繁育，人工麝香 等珍稀药材替代品实现产业化生产，常用的600多种中药材中已有300多种实现了人工种植养殖。 中药工业如何迈向高质量发展？方案绘制出"路线图"。 源头提质，建设高标准生产基地—— 中药质量的源头在于药材。方案明确，实施原料提质稳供行动，在主产区因地制宜建设一批高标准中药 原料生产基地。 "药材质量取决于产地、气候、土壤、种植养殖技术等多种因素，直接影响中药的治疗效果。"中国中医 科学院中药研究所所长郭兰萍说。 转化创新，让好药服务更多患者—— 月12日，广安门医院制剂中心生产人员进行中药提取操作。（广安门医院供图） 2025年11 "智能设备在中医药行业的应用，有助于加速中医药从'经验传 ...

Industry Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Outperform the Market" and is maintained [1]. Core Insights - The report highlights the acceleration of policy support for the optimization and transformation of the traditional Chinese medicine (TCM) industry, benefiting leading TCM companies [4][15]. - The report emphasizes the potential benefits for innovative drug companies due to the establishment of a collaborative innovation system and the promotion of new drug approvals [5][15]. - The report notes that the A-share pharmaceutical and biotechnology sector has shown a slight increase of 0.14% in the week from February 2 to February 6, 2026, outperforming the CSI 300 index by 1.47 percentage points [6][18]. Summary by Sections Industry Overview - The closing index for the pharmaceutical and biotechnology sector is 8350.08, with a weekly high of 9323.49 and a low of 6876.88 [1]. Recent Market Performance - The A-share pharmaceutical sector outperformed the CSI 300 index and the ChiNext index during the week, ranking 15th among 31 sub-industries [6][18]. - The TCM sector ranked first among sub-sectors with a weekly increase of 2.56%, while other biopharmaceutical sectors experienced a decline [18]. Policy Developments - The Ministry of Industry and Information Technology and other departments issued a plan for the high-quality development of the TCM industry from 2026 to 2030, aiming to establish a collaborative development system and support leading TCM enterprises [4][15]. - The plan includes fostering a batch of innovative TCM drugs and enhancing the protection of intellectual property for traditional brands [5][16][17]. Investment Recommendations 1. **Innovative Drugs**: The report suggests that innovative drug companies remain a strong investment choice, with a focus on companies with high certainty and low disruption expectations, such as Innovent Biologics and 3SBio [7][21]. 2. **Medical Devices**: The medical device sector is expected to see a recovery in profits, with a focus on companies like Mindray and Kangji Medical, as the impact of centralized procurement diminishes [23][24]. 3. **Traditional Chinese Medicine**: Companies like Yiling Pharmaceutical and Tianjin Zhongxin Pharmaceutical are expected to benefit from policies supporting TCM and the clearing of high inventory levels [28][29][30]. 4. **AI in Healthcare**: Companies involved in AI applications in pharmaceuticals and diagnostics, such as iCarbonX and Huada Gene, are anticipated to benefit from advancements in AI technology [32][34].

Group 1 - The core point of the article is that Jiashitang has signed a share transfer agreement with Tongrentang Group, resulting in a change of controlling shareholder to Tongrentang Group, which will hold 28.48% of Jiashitang's shares [1] - The total transfer price for the shares is 1.461 billion yuan, and after the transaction, the actual controller will change to the State-owned Assets Supervision and Administration Commission of Beijing [1] - Jiashitang's stock was suspended on January 28, 2024, with a closing price of 16.4 yuan per share and a market capitalization of 4.78 billion yuan as of January 27, 2024 [1] Group 2 - Jiashitang has been facing financial difficulties, with revenue figures from 2020 to 2024 showing a decline in net profit, reaching a ten-year low of 161 million yuan in 2024 [2][3] - The company's revenue for the first three quarters of 2025 was 14.46 billion yuan, a year-on-year decrease of 21.8%, and the net profit was 141 million yuan, down 38.81% year-on-year [3] Group 3 - Tongrentang Group, founded in 1669, aims to strengthen its distribution network through the acquisition of Jiashitang, which has a strong channel advantage in the pharmaceutical industry [5][6] - The acquisition is seen as a "strong alliance" that could help Tongrentang Group address its shortcomings in the distribution sector and create a closed-loop pharmaceutical industry chain [6][7] Group 4 - The pharmaceutical industry is experiencing a period of adjustment, with several companies undergoing control changes to enhance resource integration and business collaboration [9][10] - Recent examples include the acquisition of Tailong Pharmaceutical by Jiangyao Holdings and the control change of Yunnan Baiyao to a state-owned enterprise, indicating a trend of state-owned assets revitalizing traditional brands [9][10]

Investment Rating - The report maintains a "Buy" rating for key companies in the pharmaceutical sector, including Innovent Biologics, Efang Biologics, Tianshili, WuXi AppTec, and Mindray Medical [4][28]. Core Insights - The policy-driven upgrade of traditional Chinese medicine (TCM) industry is expected to enhance industry concentration in the medium to long term, benefiting companies with strong quality control and innovative capabilities [2][24]. - The implementation plan for high-quality development of the TCM industry aims to establish a collaborative development system by 2030, focusing on raw material supply, innovation, production quality control, and internationalization [2][23]. - The investment strategy emphasizes the importance of clinical value in the pharmaceutical sector, recommending a focus on innovative drugs and high-end medical devices [3][26]. Summary by Sections Market Review - The A-share pharmaceutical index rose by 0.14%, outperforming the CSI 300 index by 1.47 percentage points [1][16]. - The Hong Kong Hang Seng Medical Health Index fell by 1.41%, but still outperformed the Hang Seng Index by 1.65 percentage points [1][16]. Policy Insights - The Ministry of Industry and Information Technology and other departments issued a plan to enhance the TCM industry, which includes fostering leading enterprises and establishing high-standard raw material production bases [2][24]. - The plan emphasizes digitalization and sustainability, aiming to raise compliance standards and accelerate the exit of smaller companies from the market [2][25]. Company Updates - Recent clinical progress includes the NDA submission for HRS-9531 by Heng Rui Medicine and the initiation of clinical trials for various drugs by other companies [1][31][32]. - Key companies such as Yunnan Baiyao, Baiyunshan, and Taiji Group are highlighted for their strong positions in raw material supply [2][25]. Financial Forecasts - The report provides earnings per share (EPS) forecasts for key companies, with Innovent Biologics projected to have an EPS of 0.49 in 2025 and WuXi AppTec expected to reach an EPS of 5.07 in the same year [4][28]. - The pharmaceutical manufacturing industry reported a revenue decline of 1.2% year-on-year for 2025, with total revenue reaching 2,487 billion yuan [51].

Core Viewpoint - The "Craftsmanship" market in Shuangjing Street, Chaoyang District, was launched on February 6, providing residents with convenient access to traditional New Year goods and services [1] Group 1: Market Overview - The "Craftsmanship" market and the Trade Union New Year Goods Festival officially opened, following the principle of "Trade Union sets the stage, enterprises perform, and workers benefit" [4] - A total of 21 quality merchants, including Beijing Daoxiangcun, Xueji Fried Goods, Wanda Cinemas, Cuihua Building, Zhang Yiyuan, and Tongrentang, participated in the market [4] Group 2: Community Services - The market features a cultural experience area where calligraphy enthusiasts write Spring Festival couplets and "Fu" characters for residents [3] - A public service area offers consultations on elderly care policies, free haircuts, and health check-ups [3] Group 3: Support for New Employment Groups - A special "Warm Corner for New Employment Groups" was set up, where the Chaoyang District Trade Union and Shuangjing Street provided warm packages including Spring Festival couplets and lucky bags to representatives of new employment groups [5] - Health check-ups and rights protection guidance were also offered to delivery workers [5]

其实，李嘉诚敏锐地察觉到这两个港口在局势中的特殊性，立马套现离场。与此同时，李在大健康赛道 落下多枚棋子诸如和黄医药、同仁堂等，引发诸多投资者入跟风场。 如今在两广地区十分火热的"原切 芝"，是当地区逢年过节的送礼门面，其背后资本似乎与李也有密切的联系。 从京东 、 天猫 表现来看， 维特健灵 "原切芝"贴合了国内健康风向，取材自广西野生赤芝产地，并以 原切加工高度保留营养成分，一经上市就引发断货信号。 所有人都傻眼了，吵了一年的港口交易案，到头来被巴拿马"戏耍"了。 巴最高法院 一锤定音： 长和旗下两座港口的运营合同违宪，必须收回 。官方随即宣布，由丹麦马士基 集团临时接管，等后续重新招标。 李嘉诚费尽心思要卖出去的港口，转头就一无所有，到底发生了什么，中方又是什么态度？ 李嘉诚手里的两座港口，堪称印钞机。每年有1.5亿艘次大型货轮从这里进出，占整条运河集装箱吞吐 量的四成。 他经营了30年，真金白银投入18亿美元（约为124.92亿人民币），巴方的一纸判决，全部落 空。 巴拿马理由冠冕堂皇，说是续签没走公开竞标程序，违反了采购法。这事儿还真让国内专家说着了，这 就是个 早就设好的局 ，等着你往里跳。 怪不 ...

Core Viewpoint - The Beijing Cultural and Tourism Bureau has launched "Top 10 Must-Visit Lists for Spring Festival" and "Top 10 Easy Travel Routes in Beijing" to attract both domestic and international tourists during the upcoming 9-day holiday period [2][4]. Group 1: Event Highlights - A total of 240 points of interest have been selected, including 20 temple fairs and lantern festivals such as Ditan Temple Fair, Science Temple Fair, and Dadu Temple Fair [2][4]. - The event features 20 performances including "Under the Red Flag" and "Only This Green" as part of the New Year celebrations [2][4]. - There are 20 intangible cultural heritage projects showcased, including the making of cloisonné at Beijing Enamel Factory and traditional Chinese medicine culture at Tongrentang [2][4]. Group 2: Exhibitions and Attractions - The National Museum will host a Year of the Horse Spring Festival cultural exhibition, while the China Arts and Crafts Museum will feature a Spring Festival themed exhibition, each showcasing 20 quality exhibitions [2][4]. - 20 suburban villages such as Xinzhuang Village in Changping District and Huangshandian Village in Fangshan District are included as part of the travel options [5]. - Additional attractions include food, hotels, and ski resorts, contributing to the total of 240 points of interest for tourists to choose from [5].